Chinese patent medicine Tongxinluo: A review on chemical constituents, pharmacological activities, quality control, and clinical applications DOI
Qin Chen, Junbo Zou, Yajun Shi

и другие.

Phytomedicine, Год журнала: 2024, Номер 132, С. 155674 - 155674

Опубликована: Апрель 24, 2024

Язык: Английский

Chinese and western medicine treatment of myocardial fibrosis drugs DOI Creative Commons
Yuxi Zhu, Fangmei Zhang, Zhongcheng Li

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 11

Опубликована: Янв. 15, 2025

Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases, such as myocardial infarction, ischemia, and sudden cardiac death. It characterized by excessive proliferation activation fibroblasts, transformation into myofibroblasts, and, eventually, deposition the extracellular matrix, resulting in heart damage. Currently, modern drugs angiotensin-converting enzyme inhibitors, diuretics, β-blockers can improve clinical treatment, but their therapeutic effect on this disease limited, with obvious side effects high cost. Traditional Chinese medicine (TCM) has advantages multiple targets, low cost, few effects. medicines, Salvia miltiorrhiza, Astragalus, Angelica extracts, patent Qiliqiangxin capsules, Shenqi Yiqi dropping pills, Tongxinluo fibrosis. In review, current Western methods for treating are discussed. The signaling pathways targets involved treatment This review aimed to provide valuable insights ideas both basic research

Язык: Английский

Процитировано

0

Mitochondrial function: A new direction for the targeted treatment of cardiovascular diseases with Chinese herbal medicine DOI Creative Commons
Lin Yang, Liang Wang, Baofeng Yang

и другие.

Journal of Holistic Integrative Pharmacy, Год журнала: 2025, Номер 6(1), С. 91 - 104

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Isoliquiritigenin Promotes the Repair of High Uric Acid‐Induced Vascular Injuries DOI Creative Commons
Hongyan Zhou, Xinyu Song, Yingying Tian

и другие.

Smart Medicine, Год журнала: 2025, Номер 4(2)

Опубликована: Апрель 4, 2025

ABSTRACT Hyperuricemia (HUA) is a chronic metabolic disease mainly stemming from purine metabolism disorders and strongly correlated with cardiovascular diseases, gout, kidney disease, other diseases. Elevated levels of uric acid (UA) in serum will lead to vascular endothelial cell injuries directly, subsequently impairing normal functions human blood vessels. Therefore, investigating resulting HUA corresponding drug screening for its treatment are great significance the prevention Given inherent advantages multiple targets pathways, we delved into potential traditional Chinese medicine alleviating induced by detail. Through establishment an injury index library subsequent process, isoliquiritigenin proved be promising candidate promoting repair HUA‐induced injuries. It had been identified, validated efficiency evaluated using vessel‐on‐a‐chip animal tests. Additionally, network pharmacology molecular docking were further employed elucidate underlying mechanism. This work represents first demonstration isoliquiritigenin's capacity facilitate triggered high UA levels, provides valuable insights medicine.

Язык: Английский

Процитировано

0

Chinese patent medicine Tongxinluo: A review on chemical constituents, pharmacological activities, quality control, and clinical applications DOI
Qin Chen, Junbo Zou, Yajun Shi

и другие.

Phytomedicine, Год журнала: 2024, Номер 132, С. 155674 - 155674

Опубликована: Апрель 24, 2024

Язык: Английский

Процитировано

1